Therapeutic combination by T cells with anti-CD19 and anti-chimeric antigen receptors for maturation of relapsed or refractory multiple myeloma B cells

被引：0
|
作者：
Stocker, Nicolas
机构：
来源：
HEMATOLOGIE | 2019年 / 25卷 / 06期
关键词：
D O I：
10.1684/hma.2019.1502
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：285 / 285
页数：1
相关论文
共 50 条
  • [21] Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase I/II Trial
    Sang, Wei
    Shi, Ming
    Yang, Jingjing
    Cao, Jiang
    Xu, Linyan
    Yan, Dongmei
    Song, Xuguang
    Sun, Cai
    Li, Depeng
    Zhu, Feng
    Li, Zhenyu
    Zheng, Junnian
    Qiao, Jianlin
    Xu, Kailin
    BLOOD, 2019, 134
  • [22] CD19 Fc-Fusion Protein for Detection of Cells Expressing Anti-CD19 Chimeric Antigen Receptors
    De Oliveira, Satiro N.
    Wang, Jiexin
    Hollis, Roger P.
    Kohn, Donald B.
    BLOOD, 2010, 116 (21) : 1539 - 1539
  • [23] The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
    Hui Zhou
    Yuling Luo
    Sha Zhu
    Xi Wang
    Yunuo Zhao
    Xuejin Ou
    Tao Zhang
    Xuelei Ma
    BMC Cancer, 18
  • [24] Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor (CAR) T cells
    Alnabhan, Rehab
    Magalhaes, Isabelle
    Mattson, Jonas
    Uhlin, Michael
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2017, 86 (04) : 332 - 332
  • [25] Development of Anti-CD19 Chimeric Antigen Receptor T-Cells with Immune Checkpoint Silencing
    Matthes, Thomas
    Roussel-Gervais, Audrey
    Salmon, Patrick
    Ilmjarv, Sten
    Sakic, Antonija
    Krause, Karl-Heinz
    Alessandrini, Marco
    MOLECULAR THERAPY, 2021, 29 (04) : 312 - 312
  • [26] Development and in vivo evaluation of anti-CD19 chimeric antigen receptor (CAR) -yδt cells
    Kim, Nayoung
    Kim, Hyery
    Im, Ho Joon
    Koh, Kyung-Nam
    TISSUE ENGINEERING PART A, 2022, 28 : 278 - 278
  • [27] The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies: a meta-analysis
    Zhou, Hui
    Luo, Yuling
    Zhu, Sha
    Wang, Xi
    Zhao, Yunuo
    Ou, Xuejin
    Zhang, Tao
    Ma, Xuelei
    BMC CANCER, 2018, 18
  • [28] Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
    Zhou, Xuan
    Tu, Sanfang
    Wang, Chunsheng
    Huang, Rui
    Deng, Lan
    Song, Chaoyang
    Yue, Chunyan
    He, Yanjie
    Yang, Jilong
    Liang, Zhao
    Wu, Anqin
    Li, Meifang
    Zhou, Weijun
    Du, Jingwen
    Guo, Zhenling
    Li, Yongqian
    Jiao, Cheng
    Liu, Yuchen
    Chang, Lung-Ji
    Li, Yuhua
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [29] Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells
    An, Na
    Tao, Zhongfei
    Li, Saisai
    Xing, Haiyan
    Tang, Kejing
    Tian, Zheng
    Rao, Qing
    Wang, Min
    Wang, Jianxiang
    ONCOTARGET, 2016, 7 (09) : 10638 - 10649
  • [30] Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma
    Fried, Shalev
    Shkury, Eden
    Itzhaki, Orit
    Sdayoor, Inbal
    Yerushalmi, Ronit
    Shem-Tov, Noga
    Danylesko, Ivetta
    Jacoby, Elad
    Shouval, Roni
    Kedmi, Meirav
    Marcus, Ronit
    Nagler, Arnon
    Shimoni, Avichai
    Avigdor, Abraham
    LEUKEMIA & LYMPHOMA, 2023, 64 (12) : 1956 - 1963
12345